Group 1 - The core achievement of AI drug development by Heptares Pharmaceuticals is the significant increase in the target hit rate for antibody characterization from 8.7% to 78.5%, with a high purity and expression rate of 21.5% [1] - Heptares Pharmaceuticals has launched the Hu-mAtrIx AI platform, which led to the creation of the first fully human AI HCAb model, enhancing the efficiency and accuracy of antibody discovery through an integrated AI design and validation process [1] - The CEO of Heptares, Dr. Wang Jinsong, emphasized that AI in drug development is transitioning from concept validation to large-scale implementation, becoming a core infrastructure for the competitiveness of pharmaceutical companies over the next decade [1] Group 2 - According to a survey by Define Venture, 70% of major pharmaceutical companies are considering collaboration with external AI tools, indicating a strong trend towards integrating AI into global drug development [2] - Heptares Pharmaceuticals is actively building an AI-driven ecosystem for drug development, having announced the establishment of the AI + Biomedicine Ecosystem Alliance aimed at reshaping the entire drug development process [2] - The company aims to establish an AI-driven automated innovation ecosystem platform by 2028, facilitating the transition from project initiation to clinical trials in biomedicine [2]
从“大海捞针”到“AI 精选” 和铂医药AI HCAb模型赋能抗体药研发